Sonrotoclax for relapsed or refractory leukemia in children
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug (sonrotoclax) in children whose leukemia (AML or ALL) has come back or not responded to earlier treatments. The goal is to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient must have a confirmed diagnosis of acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL).
- The leukemia must have returned or not responded after at least two prior lines of treatment.
- The patient must have a performance status score of 50 or higher, meaning they are generally able to care for themselves and are not bedridden.
- Kidney and liver function must be within acceptable ranges, as determined by standard blood tests.
- The patient must not have leukemia that has spread to the central nervous system (brain or spinal cord).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
Hear when a new Relapsed Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.